← All trials
NCT06735391
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 23, 2024
- Primary completion
- Sep 30, 2026
- Completion date
- May 30, 2029
- First posted
- Dec 16, 2024
- Last posted
- Dec 16, 2024
- Enrollment
- 516
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai JMT-Bio Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.